Legal notice Clarification of off-label use Saxenda is not approved in Japan under the Pharmaceuticals and Medical Devices Act
Hims & Hers work with licensed prescribers through a network of physician-owned professional corporations operating under a managed services model, disclosed in their terms of service and SEC filings
This clarity provides a strong regulatory foundation for advancing into pivotal studies beginning Q2 2026
Medical Health How It Works Pricing FAQs Contact LegalMedical Weight Loss with GLP-1 MedicationsDr
* 1 As of 1 September, 2021, dulaglutide , an injectable GLP-1 receptor agonist, has also been fully funded with Special Authority approval
Below is an overview of these programs, effective for the January 1 through December 31, 2026 , measurement period